Applications and limitations of immunohistochemical expression of napsin-a in distinguishing lung adenocarcinoma from adenocarcinomas of other organs

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 3, 2013, Pages 191-195

  Kadivar, Maryam ^a   Boozari, Behnaz ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

adenocarcinoma; lung cancer; metastasis; Napsin A

Indexed keywords

ASPARTIC PROTEINASE; NAPSIN A; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CANCER CLASSIFICATION; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CARCINOMA; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; ASPARTIC ACID ENDOPEPTIDASES; BREAST NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, RENAL CELL; CARCINOMA, SQUAMOUS CELL; COLONIC NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGAN SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877066142     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182612643     Document Type: Article

References (11)

1. Travis WD, Travis LB, Devesa SS. Lung cancer [published erratum appears in Cancer 1995 June 15; 75 (12):2979]. Cancer. 1995;75:191-202.
2. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
3. Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 2003;41:155-162.
4. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97-102.
5. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008;132:384-396.
6. Zhang PJ, Gao HG, Pasha TL, et al. TTF1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol. 2009;28:10-18.
7. Ueno T, Linder S, Na CL, et al. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem. 2004;279: 16178-16184.
8. Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann Oncol. 2007;18(suppl 9):ixl35-ixl42.
9. Chuman Y, Bergman AC, Ueno T, et al. Napsin A, a member of the aspartic family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinoma. FEBS Lett. 1999;26;462(1-2): 129-134.
10. Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TAO2) is a useful alternative to thyroid transcription factor-1 (TTF1) for the identification of pulmonary adenocarcinoma cells in pleural effusion. Diagn Cytopathol. 2007;35:493-497.
11. Lam WK,Watkins DN. Lung cancer: future directions. Respirology. 2007;12:471-477.